SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma (formerly Cybin Inc.) is trending following its recent rebrand and NASDAQ listing under the symbolic ticker $HELP, signaling a strategic shift towards late-stage clinical development in mental health. While some investors see this as a pivotal move to enhance visibility and believe the company is undervalued compared to its psychedelic sector peers, others express skepticism, viewing the rebranding as superficial given past stock performance and concerns about dilution. The community is actively debating the implications of this transition and eagerly awaiting upcoming clinical data for its HLP003 and HLP004 programs.

Toyota Motor Corp. engages in the manufacture and sale of motor vehicles and parts. It operates through the following segments: Automotive, Financial Services, and All Other. The Automotive segment designs, manufactures, assembles and sells passenger cars, minivans, trucks, and related vehicle parts and accessories. It is also involved in the development of intelligent transport systems. The Financial Services segment offers purchase or lease financing to Toyota vehicle dealers and customers. It also provides retail leasing through lease contracts purchased by dealers. The All Others segment deals with the design, manufacture, and sale of housing, telecommunications and other businesses. The company was founded by Kiichiro Toyoda on August 28, 1937 and is headquartered in Toyota, Japan.

Toyota Motor Corporation - ADR

Toyota Motor Corp.

Toyota is trending as investors monitor evolving US-Japan tariff discussions, which significantly influence its import costs and production strategies. This comes amid a notable corporate development concerning its potential buyout of Toyota Industries, met with activist investor scrutiny. The community is also keenly observing Toyota's strategic advancements in autonomous driving through a recent Waymo partnership, while evaluating its strong hybrid sales growth against broader industry shifts and EV market challenges.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as its community emphasizes a steadfast commitment to "Bongterm" growth and positive culture, contrasting it with short-term hype. Discussions highlight the token's role within the evolving global cannabis movement and the anticipation of policy shifts impacting the sector. Members proudly position Weedcoin on Solana as a symbol of decentralized health and cultural sovereignty.

BlackRock Institutional Trust Company N.A. - iShares Gold Trust

iShares Gold Trust

iShares Gold Trust ($IAU) is witnessing substantial investor interest, fueled by escalating global geopolitical tensions, persistent inflation concerns, and a strong community perception of gold as a vital safe haven asset. Investors are actively discussing its role as a hedge against potential currency devaluation, further underscored by reports of ongoing central bank accumulation.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is heavily trending ahead of its highly anticipated 3-year topline data release for ELEVIDYS from the EMBARK study, scheduled for an upcoming Monday morning conference call. Community discussion is sharply divided, with many speculating positive results could ignite a significant price surge or a potential buyout, while others remain cautious, citing past disappointments and the persistent influence of short sellers.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A

Fortress Biotech's preferred shares ($FBIOP) are trending as the community eagerly anticipates the sale of a Priority Review Voucher (PRV) awarded to its subsidiary, Cyprium Therapeutics, following a recent drug approval. This significant cash infusion, alongside strong sales for Journey Medical's Emrosi and the expected Unloxcyt launch, is driving discussions about potential dividend reinstatement for preferred shareholders and the stock's perceived undervaluation.

Unicycive Therapeutics, Inc. engages in the development of treatment for kidney diseases. Its products include UNI-494, Renazorb, and UNI-220. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.

Unicycive Therapeutics Inc

Unicycive Therapeutics (UNCY) is trending as a recent 13G filing confirmed Millennium Management's significant ownership stake, signaling growing institutional interest. This institutional activity coincides with high community anticipation for the FDA's acceptance of the company's New Drug Application resubmission for Oxylanthanum Carbonate (OLC). Investors are optimistic about OLC's potential approval and the assignment of a PDUFA date, as the prior Complete Response Letter was related to manufacturing compliance, not the drug's efficacy.

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Teva- Pharmaceutical Industries Ltd. - ADR

Teva Pharmaceutical is currently trending due to a significant $500 million funding agreement with Royalty Pharma to accelerate its vitiligo treatment (TEV-408) and a series of positive analyst upgrades raising price targets to $35-$40. The community is buzzing about Teva's 'Pivot to Growth' strategy, driven by its innovative drug pipeline and strong financial outlook, with many anticipating a breakout to new highs.

Packaging Corporation of America engages in the production of container products. It operates through the following segments: Packaging, Paper, and Corporate and Other. The Packaging segment offers a variety of corrugated packaging products, such as conventional shipping containers. The Paper segment manufactures and sells a range of papers, including communication-based papers, and pressure sensitive papers. The Corporate and Other segment focuses on transportation assets, such as rail cars, and trucks. The company was founded in 1959 and is headquartered in Lake Forest, IL.

Packaging Corp Of America

Packaging Corp of America is actively discussed as the market evaluates its recent earnings miss and a cautious outlook, prompting a stock decline. Community sentiment is weighing the long-term benefits of the Greif acquisition against immediate challenges from soft industrial demand and rising input costs. This creates a contentious debate around the cyclical health of the packaging sector, with some anticipating further headwinds.

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Neurocrine Biosciences is trending after delivering strong earnings, fueled by robust Ingrezza sales and a positive early reception for its newly approved, first-in-class therapy, Crenessity. The community is actively discussing the substantial growth potential from these key products and a deep pipeline, alongside ongoing speculation about strategic moves within the evolving neuroscience sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Chai-samosa to paranthas and khichdi, Davos savours Indian food

At the World Economic Forum in Davos, world leaders savored an array of Indian dishes that brought a taste of India to Switzerland. Masala chai and crispy samosas were top favorites, while the aromatic biryanis delighted palates. The Tata group and HCL Tech tantalized attendees with traditional tea offerings, and Akshaya Patra delighted guests with complimentary khichdi.

Foreign funds return to Indian tech stocks on AI growth bets

Foreign investors are returning to Indian IT stocks, driven by the rising adoption of artificial intelligence and improved business visibility. Companies such as TCS, Infosys and HCL Tech are seeing strong AI-led growth, reviving sector sentiment despite near-term earnings pressure and uneven performance across firms.

HCLTech exec sees Madhya Pradesh as India's next big tech, AI hub

… 39;s potential as a tech and AI hub, citing … , Corporate Vice President - Tech Industries at HCL Technologies ( … as an attractive destination for technology investments. While acknowledging that … India's Global Tech Standing Placing Madhya Pradesh…

MP has all right ingredients to become IT hub: HCLTech’s Abhay Chaturvedi

Abhay Chaturvedi, Corporate Vice President - Tech Industries at HCL Technologies (HCLTech), expressed strong optimism about Madhya Pradesh's potential to emerge as a significant technology and AI hub, following a meeting with the Madhya Pradesh delegation on the sidelines of the World Economic Forum in Davos.

How HCLTech defied the gravity of India's four-year IT slump

Out of India's top five IT stocks, only one pulled ahead in the last four years: HCL Technologies. The others either had nil returns, or even lost value. What made the Noida-based company stand out?

HCL Technologies Ltd. Is a tech company, which engages in computer programming, consultancy, and related activities. It operates through the following segments: Information Technology and Business Services (ITBS); Engineering and Research and Development Services (ERS); and Products and Platforms segments. The Information Technolgy and Business Services segments offers technology architecture for businesses. The Engineering and Research and Development Services segment develops digital solutions for different engineering sectors. The Products and Platforms segments offer the HCLSoftware for domain-specific niche sectors. The company was founded by Shiv Nadar on November 12, 1991 and is headquartered in Noida, India.

Current Price	1,706.60
Prev Close	1,700.00
Open	1,712.70
Dividend Yield	3.39%
50-Day Moving Average	1,650.15
Beta	0.02
Avg. Volume	2.05M
PE Ratio	28.09

52-Week High	1,779.75
52-Week Low	1,302.75
Market Capitalization	4.63T
EPS (Annual)	64.16
Price to Book	6.34
Revenue Per Employee	4.99M
Enterprise Value/EBITDA	N/A

HCLTECH.NSE
HCL Technologies Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HCLTECH.NSE News

HCLTECH.NSEHCL Technologies Ltd.